What Happened?
Shares of medical device company Zimmer Biomet (NYSE: ZBH) jumped 4.9% in the afternoon session after the company announced it increased its share repurchase expectations for fiscal year 2026.
The medical device company now plans to buy back up to $1 billion of its common stock, a $250 million increase from its prior assumption. This action will be carried out under an existing $1.5 billion share repurchase authorization from February 2026. A share buyback, or repurchase, is when a company buys its own shares from the marketplace.
This reduces the number of shares available, which can increase the value of the remaining shares and often signals management's confidence that the stock is undervalued by the market.
After the initial pop the shares cooled down to $83.20, up 4.6% from previous close.
Is now the time to buy Zimmer Biomet? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Zimmer Biomet’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 3.4% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut.
New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Zimmer Biomet is down 7.6% since the beginning of the year, and at $83.20 per share, it is trading 22.8% below its 52-week high of $107.71 from August 2025. Investors who bought $1,000 worth of Zimmer Biomet’s shares 5 years ago would now be looking at only $508.04.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
